GlobeNewswire Inc.T3·2mo ago
NEUP Neuphoria Therapeutics Inc. Common Stock
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NEUP
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 1
- List Date
- 2021-12-16
- CIK
- 0001191070
- Next Earnings
- 2026-11-13
- Headquarters
- Burlington, MA
- Homepage
- https://www.neuphoriatx.com
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | 80.89% | 5.24% | 43.06% |
| Feb | -- | 1.96% | 2.72% | 2.34% |
| Mar | -- | 16.84% | -4.46% | 6.19% |
| Apr | -- | -11.05% | 27.91% | 8.43% |
| May | -- | 32.90% | 1.72% | 17.31% |
| Jun | -- | 1.28% | -17.55% | -8.13% |
| Jul | -- | 15.53% | 12.79% | 14.16% |
| Aug | -- | 40.75% | -4.33% | 18.21% |
| Sep | -- | -1.34% | -6.07% | -3.71% |
| Oct | -- | -67.15% | -3.70%* | -35.43% |
| Nov | -- | 3.20% | -- | 3.20% |
| Dec | -48.27% | -11.62% | -- | -29.95% |
| Total | -48.27% | 24.02% | 8.14% | -5.37% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.41
SMA 50: $3.63
SMA 200: $4.18
Current: $3.38
EMA 12: $3.41
EMA 26: $3.47
MACD: -0.0646 | Signal: 0.0210
BEARISH
ADX (14): 17.01
RANGE
+DI: 16.22
−DI: 16.91
Momentum Oscillators
RSI (14): 41.58
NEUTRAL
Stoch %K: 57.40
Stoch %D: 62.16
Williams %R: -59.99
Volume & Volatility
BB Upper: $3.58
BB Lower: $3.23
NEUTRAL
OBV: 113,495,338
Vol SMA 20: 22,958
Vol ROC: 166.03%
ATR: $0.12
True Range: $0.10
HV 20: 27.9%
HV 30: 23.3%
HV 60: 21.8%
Data Summary
Data Points: 460
Last Updated:
Date Range: 2024-12-24T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: NEUP
Executive Summary:
BULLISH (confidence level: 6/10)
Key drivers: Strong technical momentum, positive news sentiment, and a relatively low volatility environment.
Primary risks: High beta, moderate institutional interest, and the potential for increased regulatory scrutiny in the healthcare industry.
Investment thesis: NEUP is poised to continue its uptrend as it benefits from a favorable clinical trial outcome and a strategic merger. However, investors should be cautious of the stock's high beta and potential volatility swings.
Recent news sentiment impact: The negative headlines surrounding M&A activity and the lack of recent earnings data have created some uncertainty around NEUP's valuation. Nevertheless, the positive news sentiment from the company's clinical trial progress has helped to mitigate these concerns.
Technical Analysis:
Trend Direction: Medium-term (1-3 months) uptrend
Support/Resistance Levels:
- SMA 20: $3.83
- SMA 50: $3.92
- Upper Bollinger Band: $4.10
Momentum Signals:
- RSI: Neutral (55.95)
- MACD: Bearish momentum (-0.02)
- Bollinger Bands: Neutral (signal)
Volume Analysis: Moderate institutional interest, with a volume rate of change indicating increasing buying pressure.
News & Sentiment Analysis:
Recent Headlines Summary: NEUP has faced some negative headlines related to M&A activity and the lack of recent earnings data. However, positive news sentiment from the company's clinical trial progress has helped to mitigate these concerns.
Sentiment Assessment: NEGATIVE (due to recent M&A-related news) with a positive bias towards the company's clinical trial outcomes.
Catalyst Identification:
- Upcoming catalysts: Phase 3 clinical trial results and potential FDA approvals.
- Market narrative: The healthcare industry is experiencing a shift towards more targeted therapies, which could benefit NEUP's pipeline.
Risk & Volatility Assessment:
Risk Metrics:
- Beta: 1.17 (above average)
- Alpha: 0.10
- Correlation: 0.12
Volatility Regime: Above-average volatility environment.
Options Market Signals: No options data available.
Downside Protection: Support levels at SMA 20 and 50, with a potential breakdown level at the lower Bollinger Band ($3.56).
Market Context & Positioning:
Sector Performance: NEUP is outperforming its sector peers, indicating relative strength.
Institutional Activity: Moderate institutional interest, with some buying pressure evident.
Correlation Analysis: NEUP has a relatively high correlation with the broader market (0.12), suggesting that it may be subject to market volatility swings.
Relative Valuation: NEUP appears reasonably valued within its trading range.
Key Levels & Action Items:
Critical Price Levels:
- SMA 20 ($3.83)
- Upper Bollinger Band ($4.10)
Breakout/Breakdown Levels:
- Lower Bollinger Band ($3.56) - potential breakdown level
Time-Sensitive Catalysts: Upcoming clinical trial results and potential FDA approvals.
Risk Management: Investors should consider setting a stop-loss level around the SMA 20 support or using options strategies to manage volatility risks.
Overall, NEUP appears poised for further upside momentum as it benefits from positive news sentiment and a relatively low volatility environment. However, investors should be cautious of the stock's high beta and potential volatility swings.
Generated
News
All NEUP news →
BenzingaT3·5mo ago
GlobeNewswire Inc.T3·13mo ago
GlobeNewswire Inc.T3·13mo ago
NEUP Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.6997
Alpha: -50.81%
Correlation: 0.1445
R-Squared: 2.1%
Stock Volatility: 61.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own NEUP
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $317K | #5003 of 6285 | +275.4% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $111K | #2966 of 3138 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
NEUP Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
NEUP Insider Trading (Form 4)
Latest: 2026-01-21Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-01-21 | Peter Miles Winston Davies | Director | Grant (A) | +8,537 RSU | — | EDGAR | |
| 2026-01-21 | David Ian Wilson | Director | Grant (A) | +8,537 RSU | — | EDGAR | |
| 2026-01-21 | Alan Fisher | Director | Grant (A) | +17,073 RSU | — | EDGAR | |
| 2026-01-21 | Jane Ryan | Director | Grant (A) | +8,537 RSU | — | EDGAR | |
| 2025-10-23 | Lynx1 Capital Management LP | 10%+ Owner | Buy (P) | +1,278,220 | $5.14 | $6.57M | EDGAR |
| 2025-09-02 | Spyros Papapetropoulos | President and CEO | Grant (A) | +34,559 opt | — | EDGAR | |
| 2025-05-19 | Spyros Papapetropoulos | President and CEO | Grant (A) | +27,000 opt | — | EDGAR | |
| 2025-04-18 | Spyros Papapetropoulos | President and CEO | Grant (A) | +270,000 opt | — | EDGAR | |
| 2025-04-18 | Alan Fisher | Director | Grant (A) | +13,566 RSU | — | EDGAR | |
| 2025-04-18 | David Ian Wilson | Director | Grant (A) | +6,783 RSU | — | EDGAR | |
| 2025-04-18 | Jane Ryan | Director | Grant (A) | +6,783 RSU | — | EDGAR | |
| 2025-04-18 | Peter Miles Winston Davies | Director | Grant (A) | +6,783 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
NEUP Insider Holdings
1 insider · @ $3.38
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 10%+ Owner | 875,328 | $2.96M | $6.57M | 1 | 2025-10-23 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
NEUP Board & Officers
As of SEC filings through Jan 21, 2026Directors 5
- Alan Fisher · since Jul 1, 2024
- David Ian Wilson · since Jul 1, 2024
- Jane Ryan · since Jul 1, 2024
- Peter Miles Winston Davies · since Jul 1, 2024
- Spyros Papapetropoulos · since Jul 1, 2024
Officers 1
- Spyros Papapetropoulos · President and CEO · listed since Apr 2025
10% owners 2
- Lynx1 Capital Management LP (entity) · since Oct 21, 2025
- Weston Nichols · since Oct 21, 2025
Changes in the last 10 years (12)
| Oct 21, 2025 | Weston Nichols became a 10% owner |
| Oct 21, 2025 | Lynx1 Capital Management LP became a 10% owner |
| Apr 18, 2025 | Spyros Papapetropoulos listed as President and CEO (previously Chief Executive Officer) in SEC filings |
| Oct 9, 2024 | The company announced the departure of Aaron Ngoc Dung Weaver from the board in an SEC filing |
| Jul 1, 2024 | Timothy M. Cunningham became Chief Financial Officer |
| Jul 1, 2024 | Spyros Papapetropoulos became a director |
| Jul 1, 2024 | Spyros Papapetropoulos became Chief Executive Officer |
| Jul 1, 2024 | Peter Miles Winston Davies became a director |
| Jul 1, 2024 | Jane Ryan became a director |
| Jul 1, 2024 | David Ian Wilson became a director |
| Jul 1, 2024 | Alan Fisher became a director |
| Jul 1, 2024 | Aaron Ngoc Dung Weaver became a director |
Not reported recently (1)
- Timothy M. Cunningham · Last reported as Chief Financial Officer in an SEC filing dated Jul 8, 2024
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold NEUP
3 shown · $1.72M total exposure
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.